Research programme: subtype-selective NMDA receptor modulators - Luc Therapeutics

Drug Profile

Research programme: subtype-selective NMDA receptor modulators - Luc Therapeutics

Latest Information Update: 16 Jul 2016

Price : $50

At a glance

  • Originator Mnemosyne Pharmaceuticals
  • Developer Luc Therapeutics; Novartis
  • Class Small molecules
  • Mechanism of Action NMDA receptor modulators; NR2B N-Methyl D-Aspartate receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Research Depressive disorders
  • No development reported Alzheimer's disease; Attention-deficit hyperactivity disorder; Brain injuries; Schizophrenia; Stroke

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for research development in Alzheimer's-disease in USA
  • 16 Jul 2016 No recent reports of development identified for research development in Attention-deficit-hyperactivity-disorder in USA
  • 16 Jul 2016 No recent reports of development identified for research development in Brain injuries in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top